NEW YORK, Aug. 1, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced it obtained a Notice of Allowance from the European Patent Office (EPO) for OX1, which has been licensed to ViroPharma for Friedrich's Ataxia and other neurodegenerative diseases. Separately, the company received a similar notice from the Israeli patent office for the RECALL-VAX platform technology that underlies RV03, its first-in-class bi-specific vaccine targeting beta amyloid and delta tau for the treatment and prevention of Alzheimer's disease.
The OX1 patent relates to a new salt form found to be useful to increase the purity of the compound during manufacture. The new patent potentially extends the patent coverage in Europe by several years. Corresponding patent applications are pending in the United States and Japan.
RECALL-VAX is a chimeric peptide vaccine used to produce highly specific immune responses and to avoid potential autoimmune responses. Its lead candidate, RV03 is a preclinical, first-in-class, dual acting peptide vaccine designed to induce an immune response against beta amyloid and delta tau. Delta tau is thought to be a pathological form of tau protein generated prior to the formation of neurofibrillary tangles in the brain of Alzheimer's patients. Patents for RECALL-VAX have been granted in the United States, Europe and Japan.
"These new patent allowances underscore the depth of Intellect's global patent portfolio comprising of some fifteen patent estates covering the company's platform technologies and products in development," said Dr. Daniel Chain, chairman and CEO of Intellect Neurosciences. "We have entered into four new license agreements since 2008, and continue to attract interest from global pharmaceutical companies interested in collaborating on our programs for promising next generation therapies for the treatment of neurodegenerative diseases."
About Intellect Neurosciences
Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates.
For more information, please visit www.intellectns.com.
Safe Harbor Statement Regarding Forward-‐Looking Statements:
The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-‐looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-‐looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333-‐128226), filed on October 13, 2011, and in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2012, which was filed on May 14, 2012.